Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.66 |
| ▸ | CA2 | P00918 | 5/20 | 0.66 |
| ▸ | CA12 | O43570 | 4/20 | 0.66 |
| ▸ | CA7 | P43166 | 3/20 | 0.66 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.47 |
| ▸ | HTR2B | P41595 | 2/20 | 0.47 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4235994 | 0.98 | CA1 (0.63) | CA1CA2CA12CA7CA14 | |
| SCHEMBL7909287 | 0.98 | CA1 (0.63) | CA1CA2CA12CA7CA14 | |
| SCHEMBL7427733 | 0.96 | CA1 (0.60) | CA1CA2CA12CA7CA14 | |
| Hydrochloric Acid SCHEMBL11153185 | 0.94 | CA1 (0.58) | CA1CA2CA12CA7CA14 | |
| SCHEMBL6945238 | 0.94 | CA1 (0.58) | CA1CA2CA12CA7CA14 | |
| Trifluoroacetic Acid SCHEMBL8125900 | 0.83 | KDM4E (0.51) | CA1CA2CA12CA7CA14 | |
| SCHEMBL9646446 | 0.80 | CA12 (0.61) | CA1CA2CA12CA7CA14 | |
| SCHEMBL1546679 | 0.79 | CA12 (0.66) | CA1CA2CA12CA7CA14 | |
| SCHEMBL7909284 | 0.79 | CA12 (0.66) | CA1CA2CA12CA7CA14 | |
| SCHEMBL12828070 | 0.79 | CA12 (0.66) | CA1CA2CA12CA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4171459-A | Manufacture of α-naphthol | BASF AKTIENGESELLSCHAFT (DE) | 1979-10-16 | — | — | US | claimed |
| US-12036208-B2 | Methods for treating neurodegenerative disorders | ALZHEON, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| CN-101039904-B | Is suitable for treating dopamine D3Heterocyclic compounds for receptor-modulated responsive disorders | ABBOTT GMBH & CO KG | 2014-09-24 | — | — | CN | disclosed |
| US-8470810-B2 | Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2013-06-25 | — | — | US | disclosed |
| US-20110160176-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2011-06-30 | — | — | US | disclosed |
| US-7851463-B2 | Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2010-12-14 | — | — | US | disclosed |
| US-20080045493-A1 | Heterocyclic Compounds Suitable For Treating Disorders That Respond To Modulation Of The Dopamine D3 Receptor | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-02-21 | — | — | US | disclosed |
| CN-101039904-A | Is suitable for treating dopamine D3Heterocyclic compounds for receptor-modulated responsive disorders | ABBOTT GMBH & CO KG (DE) | 2007-09-19 | — | — | CN | disclosed |
| EP-1814849-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006040182-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2006-04-20 | — | — | WO | disclosed |
| US-4576973-A | ADSORBENT BEAD | CASSELLA AKTIENGESELLSCHAFT (DE) | 1986-03-18 | — | — | US | disclosed |
| US-4552905-A | VINYL-SUBSTITUTED PYRIDINE, QUINOLINE, ISO-QUINOLINE, OR PYRAZINE;N-VINYLAMIDE, CROSSLINKER | CASSELLA AKTIENGESELLSCHAFT (DE) | 1985-11-12 | — | — | US | disclosed |
| EP-0134921-A1 | Copolymer, process for its preparation and its use as a sorbent | CASSELLA Aktiengesellschaft (DE) | 1985-03-27 | — | — | EP | disclosed |
| EP-0131179-A1 | Copolymer, process for its preparation and its use as a sorbent | CASSELLA Aktiengesellschaft (DE) | 1985-01-16 | — | — | EP | disclosed |
| US-4465506-A | Herbicidal N-[heterocyclicaminocarbonyl]-1H-indene and tetrahydronaphthalene sulfonamides | E. I. DUPONT DE NEMOURS AND COMPANY (US) | 1984-08-14 | — | — | US | disclosed |
| EP-0082681-A2 | Herbicidal sulfonamides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-06-29 | — | — | EP | disclosed |
| US-4171459-A | Manufacture of α-naphthol | BASF AKTIENGESELLSCHAFT (DE) | 1979-10-16 | — | — | US | disclosed |
| US-4143050-A | MANUFACTURE OF 3-HALOSULFONYLTHIOPHENE-CARBOXYLIC ACID COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 1979-03-06 | — | — | US | disclosed |
| US-4117019-A | MANUFACTURE OF O-BENZYLTOLUENES | BASF AKTIENGESELLSCHAFT (DE) | 1978-09-26 | — | — | US | disclosed |
| US-3928472-A | Process for the production of indanol-(4) and indanol-(5) | RUETGERSWERKE AG | 1975-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12036208-B2 | Methods for treating neurodegenerative disorders | NLN, CLN6, SNCA | CA1 1420/4885CA2 1855/4885CA12 3265/4885 |
| US-20110160176-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | DRD3, CHRNA3, CHRM3 | CA1 3394/4885CA2 2933/4885CA12 3135/4885 |
| US-20080045493-A1 | Heterocyclic Compounds Suitable For Treating Disorders That Respond To Modulation Of The Dopamine D3 Receptor | DRD3, MC3R, CHRNA3 | CA1 3382/4885CA2 2979/4885CA12 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.